AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11550937 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable carmustine polymer
Number of subjects: 0
Study 11550937 — intervention group
Group type: COMPARATOR
Intervention: Other regression models for censored survival data
Number of subjects: 0
Study 9692422 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg
Number of subjects: 17
Study 9692422 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 17
Study 9692422 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin 7500iu
Number of subjects: 17
Study 7871610 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin once daily (prophylaxis group, n = 176)
Number of subjects: 339
Study 7871610 — intervention group
Group type: COMPARATOR
Intervention: Control group without prophylaxis (n = 163)
Number of subjects: 339
Study 3060065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine catheter aspiration cytology of the peritoneal cavity
Number of subjects: 98
Study 3060065 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical assessment (Control)
Number of subjects: 98
Study 30790377 — intervention group
Group type: EXPERIMENTAL
Intervention: High understaffing
Number of subjects: 2207
Study 30790377 — intervention group
Group type: EXPERIMENTAL
Intervention: Low understaffing
Number of subjects: 2207
Study 30790377 — intervention group
Group type: COMPARATOR
Intervention: Sufficient staffing
Number of subjects: 2207
Study 28806194 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-month (PP3M) treatment
Number of subjects: 48
Study 28806194 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate 1-month (PP1M) treatment
Number of subjects: 48
Study 25315181 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced REP (customized manual/training/facilitation)
Number of subjects: 384
Study 25315181 — intervention group
Group type: COMPARATOR
Intervention: Standard REP (manual/training)
Number of subjects: 384
Study 23269821 — intervention group
Group type: EXPERIMENTAL
Intervention: Advergame promoting energy-dense snacks
Number of subjects: 270
Study 23269821 — intervention group
Group type: EXPERIMENTAL
Intervention: Advergame promoting fruit
Number of subjects: 270
Study 23269821 — intervention group
Group type: EXPERIMENTAL
Intervention: Advergame promoting nonfood products
Number of subjects: 270
Study 23269821 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 270
Study 21565464 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (up to 300 mg/day)
Number of subjects: 35
Study 21565464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 18489665 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous etanercept treatment (50 mg twice weekly for 12 weeks, then 50 mg once weekly for 12 weeks)
Number of subjects: 0
Study 18489665 — intervention group
Group type: COMPARATOR
Intervention: Interrupted etanercept treatment (single round of discontinuation and re-treatment with etanercept 50 mg once weekly for the second 12 weeks)
Number of subjects: 0
Study 16717337 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-injection axillary brachial plexus block
Number of subjects: 90
Study 16717337 — intervention group
Group type: COMPARATOR
Intervention: Midhumeral block
Number of subjects: 90
Study 14979502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 39
Study 14979502 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 39
Study 11525091 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned vaginal delivery (VD) in non-randomised group
Number of subjects: 236
Study 11525091 — intervention group
Group type: COMPARATOR
Intervention: Primary caesarean section (CS) in non-randomised group
Number of subjects: 236
Study 11525091 — intervention group
Group type: COMPARATOR
Intervention: Planned caesarean section (CS) in randomized group
Number of subjects: 236
Study 11525091 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned vaginal delivery (VD) in randomized group
Number of subjects: 236
Study 8998184 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational approach
Number of subjects: 400
Study 8998184 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling approach
Number of subjects: 400
Study 8998184 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 400
Study 8502513 — intervention group
Group type: COMPARATOR
Intervention: BA + PL (0.2 mg albuterol with placebo three times a day)
Number of subjects: 40
Study 8502513 — intervention group
Group type: COMPARATOR
Intervention: BA + CS (0.2 mg albuterol with budesonide three times a day)
Number of subjects: 40
Study 8502513 — intervention group
Group type: EXPERIMENTAL
Intervention: BA + CS
Number of subjects: 40
Study 3318423 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of nabumetone administered at night
Number of subjects: 41
Study 3318423 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of nabumetone given at night
Number of subjects: 41
Study 3318423 — intervention group
Group type: COMPARATOR
Intervention: 250 mg of naproxen in the morning and 500 mg at night
Number of subjects: 41
Study 3318423 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg twice daily)
Number of subjects: 41
Study 3318423 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50 mg three times daily)
Number of subjects: 41
Study 31765687 — intervention group
Group type: EXPERIMENTAL
Intervention: 112.5 kcal beverage
Number of subjects: 83
Study 31765687 — intervention group
Group type: COMPARATOR
Intervention: 0 kcal beverage
Number of subjects: 83
Study 31765687 — intervention group
Group type: EXPERIMENTAL
Intervention: High viscous beverage
Number of subjects: 83
Study 31765687 — intervention group
Group type: COMPARATOR
Intervention: Low viscous beverage
Number of subjects: 83
Study 30695080 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple bouts of walking
Number of subjects: 68
Study 30695080 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous walking
Number of subjects: 68
Study 30695080 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 27471838 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 index of reactivity (IR)
Number of subjects: 968
Study 27471838 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 index of reactivity (IR)
Number of subjects: 968
Study 27471838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study 24912485 — intervention group
Group type: COMPARATOR
Intervention: Standard Dose (SD) oseltamivir
Number of subjects: 52
Study 24912485 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Dose (DD) oseltamivir
Number of subjects: 52
Study 22652917 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised off-season conditioning program
Number of subjects: 44
Study 22652917 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised off-season conditioning program
Number of subjects: 44
Study 21613353 — intervention group
Group type: COMPARATOR
Intervention: Testosterone (men)
Number of subjects: 20
Study 21613353 — intervention group
Group type: COMPARATOR
Intervention: Estradiol (women)
Number of subjects: 20
Study 21613353 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH or GHRP-2
Number of subjects: 20
Study 21613353 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study 19289342 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management (MTM) services for hypertension and diabetes management
Number of subjects: 52
Study 19289342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MTM services)
Number of subjects: 52
Study 16687712 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 mug per day)
Number of subjects: 411
Study 16687712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 16687712 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 411
Study 16687712 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide and Placebo
Number of subjects: 411
Study 15609475 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietic agents
Number of subjects: 0
Study 15609475 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 0
Study 15609475 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programs, educational support, counseling, energy conservation strategies
Number of subjects: 0
Study 11291531 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 25
Study 11291531 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 25
Study 9433148 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape molasses (GM) in infants with IDA
Number of subjects: 56
Study 9433148 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (FS) in infants with IDA
Number of subjects: 56
Study 9433148 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape molasses (GM) in non-anemic infants
Number of subjects: 56
Study 9433148 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (FS) in non-anemic infants
Number of subjects: 56
Study 7960548 — intervention group
Group type: EXPERIMENTAL
Intervention: Home automated intermittent peritoneal dialysis (IPD)
Number of subjects: 16
Study 3236744 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied dexamethasone eyedrops 0.1% with local antibiotics
Number of subjects: 0
Study 3236744 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (an inhibitor of cyclooxygenase)
Number of subjects: 0
Study 31799796 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dedicated ventilator for MPV (PB560, Covidien) with a plastic angled mouthpiece
Number of subjects: 20
Study 31799796 — intervention group
Group type: COMPARATOR
Intervention: Dedicated MPV ventilator (Trilogy 100, Philips Respironics) without backup rate and kiss trigger combined with a silicone straw mouthpiece
Number of subjects: 20
Study 30284454 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective social isolation
Number of subjects: 2541
Study 30284454 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective social isolation
Number of subjects: 2541
Study 28922159 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing Group (SG)
Number of subjects: 59
Study 28922159 — intervention group
Group type: EXPERIMENTAL
Intervention: Painting Group (PG)
Number of subjects: 59
Study 26360283 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation strategy (behavioural support and drugs)
Number of subjects: 97
Study 26360283 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 97
Study 24342651 — intervention group
Group type: EXPERIMENTAL
Intervention: Eravacycline at 1.5 mg/kg q24h
Number of subjects: 139
Study 24342651 — intervention group
Group type: EXPERIMENTAL
Intervention: Eravacycline at 1.0 mg/kg q12h
Number of subjects: 139
Study 24342651 — intervention group
Group type: COMPARATOR
Intervention: Ertapenem at 1 g q24h
Number of subjects: 139
Study 22964320 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track surgery
Number of subjects: 70
Study 22964320 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 70
Study 19574947 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil (50 mg for 90 days)
Number of subjects: 100
Study 19574947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19574947 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil
Number of subjects: 100
Study 17306648 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - conjugated estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg
Number of subjects: 45
Study 17306648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15105403 — intervention group
Group type: EXPERIMENTAL
Intervention: Promegetone 0.5 mg plus estradiol 2 mg (E) per day
Number of subjects: 78
Study 15105403 — intervention group
Group type: COMPARATOR
Intervention: Promegetone 0.5 mg plus estradiol placebo (PL)
Number of subjects: 78
Study 12880955 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for neuroblastoma at 1 year of age
Number of subjects: 2581188
Study 12880955 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 2581188
Study 9650542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous losartan
Number of subjects: 11
Study 9650542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral losartan
Number of subjects: 11
Study 7544684 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline-dextran (HSD)
Number of subjects: 20
Study 7544684 — intervention group
Group type: COMPARATOR
Intervention: Control (no HSD)
Number of subjects: 20
Study 2474257 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 litres of crystalloid solution
Number of subjects: 60
Study 2474257 — intervention group
Group type: COMPARATOR
Intervention: 1 litre of colloid solution (hydroxyethyl starch)
Number of subjects: 60
Study 591135 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site urine testing (by the EMIT system) with immediate feedback of results to patients and staff
Number of subjects: 0
Study 591135 — intervention group
Group type: COMPARATOR
Intervention: Off-site urine testing (by thin-layer chromatography)
Number of subjects: 0
Study 31416496 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressively integrated sandplay therapy
Number of subjects: 50
Study 31416496 — intervention group
Group type: COMPARATOR
Intervention: Structured teaching and auditory integration training (AIT)
Number of subjects: 50
Study 28917373 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Rosa damascena oil
Number of subjects: 40
Study 28917373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25970668 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast Omission
Number of subjects: 10
Study 25970668 — intervention group
Group type: COMPARATOR
Intervention: Breakfast Consumption
Number of subjects: 10
Study 23506514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral program (CB; n = 166)
Number of subjects: 518
Study 23506514 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific control (NSp; n = 175)
Number of subjects: 518
Study 23506514 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control (NIC; n = 177)
Number of subjects: 518
Study 21451092 — intervention group
Group type: EXPERIMENTAL
Intervention: Various physical therapy interventions
Number of subjects: 42
Study 19349712 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS E2/MPA (transdermal estradiol 50 microg + oral medroxyprogesterone acetate 10 mg/day for 12 days)
Number of subjects: 60
Study 19349712 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/day)
Number of subjects: 60
Study 19349712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16690058 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation and ICSI (in patients with unilateral or bilateral cystectomy)
Number of subjects: 156
Study 16690058 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation and ICSI (in patients with unilateral cystectomy)
Number of subjects: 156
Study 16690058 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with tubal factor infertility)
Number of subjects: 156
Study 14767865 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor (omega-3 polyunsaturated fatty acid concentrate) 4 capsules daily for 8 weeks
Number of subjects: 14
Study 11244133 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sodium thiosulfate (0.5% in petrolatum)
Number of subjects: 4101
Study 9260445 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 12
Study 9260445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9260445 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-ADHD children)
Number of subjects: 12
Study 8501418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (Cs) treatment at an initial dose of 10 mg kg‐1 BW day‐1 for 12 months
Number of subjects: 105
Study 8501418 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 105
Study 8501418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (Cs) treatment
Number of subjects: 105
Study 3519096 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose trimipramine (25 to 75 mg/day)
Number of subjects: 36
Study 3519096 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 31618768 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid-targeted biopsies
Number of subjects: 200
Study 31618768 — intervention group
Group type: COMPARATOR
Intervention: Nontargeted biopsies (Seattle protocol)
Number of subjects: 200
Study 30521639 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs (rivaroxaban, dabigatran, apixaban)
Number of subjects: 149180
Study 30521639 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 149180
Study 30521639 — intervention group
Group type: EXPERIMENTAL
Intervention: Total PBS anticoagulant expenditure
Number of subjects: 149180
Study 29231566 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion combined with autohemotherapy of acupoint injection
Number of subjects: 75
Study 29231566 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion
Number of subjects: 75
Study 29231566 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study 25301344 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 4 g with tazobactam 0.5 g intravenously by 1-hour infusion every 8 hours
Number of subjects: 3
Study 22735756 — intervention group
Group type: EXPERIMENTAL
Intervention: RC-3095 (3 mg/kg, intravenous) administered over a period of 12 h in human patients with sepsis.
Number of subjects: 0
Study 22735756 — intervention group
Group type: EXPERIMENTAL
Intervention: RC-3095 (3 mg/kg, subcutaneously) in male Wistar rats subjected to cecal ligation and puncture (CLP).
Number of subjects: 0
Study 22735756 — intervention group
Group type: EXPERIMENTAL
Intervention: RC-3095 (10 ng/mL) in RAW 264.7 culture cells exposed to LPS or TNF-α.
Number of subjects: 0
Study 15986192 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.42 mg/kg d,l-dexamphetamine
Number of subjects: 20
Study 15986192 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.42 mg/kg d-methamphetamine
Number of subjects: 20
Study 15986192 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.42 mg/kg d,l-methamphetamine
Number of subjects: 20
Study 15986192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11929743 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity group intervention including home assessments, individualized action plans, education, social support, and materials to reduce exposures over 12 months
Number of subjects: 274
Study 11929743 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity group intervention including initial assessment, home action plan, limited education, and bedding encasements
Number of subjects: 274
Study 9588402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 40
Study 9588402 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 40
Study 8535711 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg epirubicin combined with 10 MU alpha 2b‐IFN, intravesically in 50 mL sterile buffer solution
Number of subjects: 81
Study 8535711 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg epirubicin
Number of subjects: 81
Study 8535711 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection (TUR) alone
Number of subjects: 81
Study 2243428 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug regimens and diet
Number of subjects: 72
Study 2243428 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 347042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 85
Study 347042 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 85
Study 347042 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 85
Study 347042 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli K100
Number of subjects: 85
Study 30458740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitterant formulation
Number of subjects: 43
Study 30458740 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfumed formulation
Number of subjects: 43
Study 30458740 — intervention group
Group type: COMPARATOR
Intervention: Plain formulation
Number of subjects: 43
Study 27585777 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Tooth Mousse
Number of subjects: 44
Study 27585777 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro 5000
Number of subjects: 44
Study 27585777 — intervention group
Group type: COMPARATOR
Intervention: 50-ppm sodium fluoride solution
Number of subjects: 44
Study 27585777 — intervention group
Group type: COMPARATOR
Intervention: Artificial saliva
Number of subjects: 44
Study 26217423 — intervention group
Group type: EXPERIMENTAL
Intervention: Online SBIRT training
Number of subjects: 40
Study 26217423 — intervention group
Group type: COMPARATOR
Intervention: In-person SBIRT training
Number of subjects: 40
Study 23724518 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin treatment and letrozole along with GnRH antagonist protocol (Group 1)
Number of subjects: 50
Study 23724518 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin treatment along with GnRH antagonist protocol (Group 2)
Number of subjects: 50
Study 21036071 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderated journal club
Number of subjects: 443
Study 21036071 — intervention group
Group type: COMPARATOR
Intervention: Internet journal club
Number of subjects: 443
Study 18721002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet 90 mg once daily for 5 days
Number of subjects: 12
Study 18721002 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 2 mg alone
Number of subjects: 12
Study 17345916 — intervention group
Group type: EXPERIMENTAL
Intervention: MI with feedback
Number of subjects: 122
Study 17345916 — intervention group
Group type: EXPERIMENTAL
Intervention: MI without feedback
Number of subjects: 122